SOURCE: Burrill & Company

May 26, 2011 09:00 ET

Life Sciences Executives, Policymakers Gather to Discuss Emerging Opportunities in Pan-Asian Markets at Burrill & Company Meeting

SAN FRANCISCO, CA--(Marketwire - May 26, 2011) - Pan-Asian nations, once viewed mostly as a source of inexpensive labor, have emerged as strong growth markets and engines of innovation. Companies around the world are racing to do business in the region that extends from the research centers of Australia to the explosively growing healthcare market in China.

The Burrill Pan-Asia Life Sciences Meeting will explore the opportunities and barriers to doing business throughout Pan-Asia and the lessons learned by companies that have established a presence there. The half-day meeting will be held on June 26, 2011 in Washington, D.C., just ahead of the BIO 2011 International Convention.

Industry leaders will discuss incentives designed to attract global life sciences companies to their countries. In addition, CEOs and other senior executives will provide a ground-level view and give their own experiences about doing business in Pan-Asian countries, such as China, India, South Korea, Malaysia, Singapore, Taiwan, Australia, and New Zealand. Biotech industry visionary G. Steven Burrill, CEO of Burrill & Company, will kick off the meeting with an overview of the state of global biotechnology and Pan-Asia's emerging role within it.

The Burrill Pan-Asia Life Sciences Meeting presents an ideal opportunity to learn why Pan-Asia is becoming one of the fastest growing areas in the global life sciences sector and to network with CEOs, and industry managers working in these countries. For more information or to register for the conference, please go to:

Mr. Burrill will also present his annual State of the Industry Report at the BIO International Convention on Tuesday, June 28, 2011 at 2:00 p.m. His presentation marks the publication of Biotech 2011-Life Sciences: Looking Back to See Ahead, Burrill & Company's 25th annual report on the biotechnology industry. At a time when governments are constrained by rising global healthcare costs, pharmaceutical companies are struggling with declining R&D productivity and the loss of billions in revenues to new generic competition, and regulatory barriers are rising, Mr. Burrill will discuss some of the key events that have shaped the industry and what companies will need to do in order to remain competitive today.

If you are attending the BIO International Convention, be sure to visit Burrill & Company in the BIO Exhibit Hall at Booth 3116 where you can learn about the company's activities in venture capital, merchant banking, private equity, and media.

About Burrill & Company
Founded in 1994, Burrill & Company is a diversified global financial services firm focused on the life sciences industry. With more than $1 billion in assets under management, the firm's businesses include venture capital, private equity, merchant banking and media. By leveraging the scientific and business networks of its investment team, Burrill & Company has established unrivaled access and visibility in the life sciences industry. This unique combination of resources and capabilities enables the company to provide life sciences companies with capital, management expertise, insight, market intelligence and analysis through its investments, conferences, and publications. Headquartered in San Francisco, the company oversees a global network of offices throughout the United States, Latin America, Europe and Asia. For more information visit:

The Burrill Personalized Medicine Meeting
October 3-4, 2011, Burlingame, CA

To purchase a copy of Biotech 2011-Life Sciences: Looking Back to See Ahead, go to

Contact Information